Navigation Links
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
Date:2/2/2009

cs License Application (BLA) with the FDA in the second quarter of 2009. HGS will receive an additional $15 million from the U.S. Government upon FDA licensure of ABthrax.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing. ABthrax(TM) (raxibacumab) is in late-stage development for inhalation anthrax, and HGS also has three drugs in clinical development for the treatment of cancer, including two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, which GSK has advanced to Phase 3 development as a potential treatment for coronary heart disease.

For more information about HGS, please visit the Company's web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

For an Electronic Press Kit on this announcement, please click here: http://www.firstlinemedia.com/epk/hgs/.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B ar
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
2. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
3. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
4. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
5. 2008 Human Research Protection Award Recipients Announced
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
8. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
9. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
10. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
11. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... Extensiv hydrolysierte Milch ... Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ist die ... Kleinkindern. Der bisher übliche Umgang mit dieser ... bzw. deren stillenden Mütter Milchproteine zu vermeiden. ... einer beträchtlichen Anzahl von Kindern der Aufbau ...
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
... 2011 Aethlon Medical, Inc. (OTCBB: ... to address infectious disease and cancer, announces that ... a company overview, discuss recent developments and review ... & Medical Technologies Virtual Conference.   ...
... June 7, 2011 CMR Institute , the leading ... announces the addition of two new e-modules to help representatives ... (ACA): The Affordable Care ... Accountable Care Organizations and Future Healthcare Delivery ...
Cached Medicine Technology:Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 2Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 3CMR Institute Adds e-Modules Addressing Healthcare Reform's Impact on Pharmaceutical Industry 2
(Date:10/30/2014)... Calif. (PRWEB) October 30, 2014 ... mutually exclusive concepts in the medical-grade skin care ... the development of uniquely potent topical dermatological products, ... System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant ... glycolic acid concentrations (50% and 70%) and a ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, 2014 ... cancer who also have certain heart problems may increase their ... suggests. , , The therapy in question is called androgen deprivation ... of male hormones to prevent the growth of cancer cells, ... hormone therapy was linked to triple the risk of heart-related ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Horse ... therapeutic horseback riding to special needs individuals in the ... on Saturday, November 15 from 10-2:00 p.m. at Bailey's ... is open to the public and is designed to ... , Admission to the HSS Round-Up is free. Ticket ...
(Date:10/30/2014)... October 30, 2014 The annual meeting ... came to a close on Saturday, October 18th, marking ... Society’s inception in 1989. NAMS is North America’s leading ... of life of all women during midlife and beyond ... over 2,000 physicians and thought leaders from fields as ...
(Date:10/30/2014)... By Amy Norton ... -- Exposure to a common plastics, chemical during pregnancy may ... study hints. Researchers found that baby boys born to ... to have a shorter anogenital distance -- the space between ... womb, and it,s considered a marker of exposure to androgens ...
Breaking Medicine News(10 mins):Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3
... 11 a.m. in Richmond RICHMOND, Va., March 3 ... press conference on March 5 in Richmond to call on ... Virginia Congressional Delegation to support legislation that would grant the ... The House Energy and Commerce Committee is scheduled to ...
... Consuming two or more drinks per day could ... 22 percent, according to data published in Cancer ... American Association for Cancer Research. , "Our findings ... to no more than two alcoholic beverages per day ...
... provides insight into how a short burst in nitrite can ... stress and assaults such as heart attacks. In this study, ... University School of Medicine have demonstrated for the first time ... are sufficient to have a lasting impact on the heart ...
... that multiple types of child maltreatment are robust risk ... multi-year study that explored the influence of social environment ... research, which appears in the current issue of ... five or more alcoholic drinks on a single occasion ...
... AIRM ) will report financial results for the ... the market on Tuesday, March 10, 2009. The Company ... at 4:15 p.m. Eastern to discuss these results. Interested ... or (706) 643-8826 (international) or by accessing the web cast ...
... children are prone to, study suggests , , TUESDAY, March ... inattentive could be susceptible to gambling by the time ... Impulsiveness can lead to many problems, such as dropping ... and now gambling has been added to the list, ...
Cached Medicine News:Health News:Virginia Faith Leaders Call on Sens. Webb & Warner to Support Legislation to Protect Kids From Tobacco 2Health News:New study shows how spikes in nitrite can have 2Health News:New study shows how spikes in nitrite can have 3Health News:How multiple childhood maltreatments lead to greater adolescent binge drinking 2Health News:How multiple childhood maltreatments lead to greater adolescent binge drinking 3Health News:Impulsive Kindergartners May Turn to Gambling 2Health News:Impulsive Kindergartners May Turn to Gambling 3
... EBV laboratory diagnosis is generally confirmed by a ... the disease however, is not indicated by the ... in 10 - 20 percent of children. ... necessary to fully ascertain the stage of EBV ...
... Bard® Biopsy Instrument and Needle is specially ... goal: a large quality, reliable core sample. ... featuring ultra-sharp tips and polished surfaces for ... of biopsy systems and needle sizes assures ...
... to bring efficiency and quality to routine ... superior technology of fluorescent flow cytometry with ... sampling or batch processing are easily accommodated ... in high volume laboratories. Fluorescent flow ...
... The IsoSleeve™ Source Delivery System incorporates ... design that provides the confidence that each ... prior to implant. Unlike other preloaded needle ... verification of the loading configuration giving you ...
Medicine Products: